WO2014194930A1 - Extemporaneous preparation of autologous fibrin - Google Patents
Extemporaneous preparation of autologous fibrin Download PDFInfo
- Publication number
- WO2014194930A1 WO2014194930A1 PCT/EP2013/061397 EP2013061397W WO2014194930A1 WO 2014194930 A1 WO2014194930 A1 WO 2014194930A1 EP 2013061397 W EP2013061397 W EP 2013061397W WO 2014194930 A1 WO2014194930 A1 WO 2014194930A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chamber
- outside
- plasma
- outlet
- treatment
- Prior art date
Links
- 108010073385 Fibrin Proteins 0.000 title claims abstract description 25
- 102000009123 Fibrin Human genes 0.000 title claims abstract description 25
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 229950003499 fibrin Drugs 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims description 9
- 210000004369 blood Anatomy 0.000 claims abstract description 23
- 239000008280 blood Substances 0.000 claims abstract description 23
- 238000002955 isolation Methods 0.000 claims abstract description 6
- 108010049003 Fibrinogen Proteins 0.000 claims description 31
- 102000008946 Fibrinogen Human genes 0.000 claims description 31
- 229940012952 fibrinogen Drugs 0.000 claims description 31
- 108090000190 Thrombin Proteins 0.000 claims description 29
- 229960004072 thrombin Drugs 0.000 claims description 29
- 238000012546 transfer Methods 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 14
- 239000012503 blood component Substances 0.000 claims description 11
- 239000000306 component Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 230000002572 peristaltic effect Effects 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000000007 visual effect Effects 0.000 claims description 4
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- 230000008569 process Effects 0.000 abstract description 7
- 210000002381 plasma Anatomy 0.000 description 33
- 239000012530 fluid Substances 0.000 description 16
- 210000004623 platelet-rich plasma Anatomy 0.000 description 8
- 210000001772 blood platelet Anatomy 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 230000037452 priming Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 206010003504 Aspiration Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0415—Plasma
- A61M2202/0425—Thrombin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
- A61M2205/123—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit with incorporated reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
- A61M2205/125—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit with incorporated filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
- A61M2205/127—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit with provisions for heating or cooling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
- A61M2205/128—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit with incorporated valves
Abstract
Autologous fibrin is prepared extemporaneously from either a full blood sample or a prepared volume of poor platelet plasma sample when the latter is subject to a dedicated treatment and combined isolation process performed by means of a removable single-use device (2) wherein blood or plasma components are separated and subsequently treated individually to be eventually combined by the user outside the system. The said system comprises a platform (1) and a removable single-use device both being designed to cooperate mechanically.
Description
Extemporaneous Preparation of Autologous Fibrin
Field of the Invention The invention relates generally to the preparation of tissues and cells including a combination of fibrinogen and thrombin. The invention refers more particularly to a system as well as to a device designed for the isolation of blood or plasma protein components and their use, in particular the isolation and concentration of plasma fractions rich in fibrinogen and thrombin from a single blood donor and their subsequent combination to afford e.g . autologous fibrin glues or fibrin gels or as a 3D fibrinous matrix for tissue and cell engineering purposes. Background of the Invention
Tissue adhesive in the form of fibrin glues and sealants have been proposed for use to control bleeding, seal wound edges and to promote wound healing in a variety of traumatic and surgical situations. Furthermore fibrin sealants can be used to act as a biological matrix to facilitate and enhance cell survival, cell differentiation and cell proliferation, with emphasis on growth factors and stem cells. Fibrin glues or fibrin gels contain fibrinogen and thrombin which, when mixed together, form a solidified fibrin mesh of fibers, the basic substance of strength in hemostasis or clotting. Fibrin is used intra-operatively to affect hemostasis, sealing of wound edges or used as an adhesion prevention barrier.
In Europe and elsewhere commercial fibrin glues were prepared from fibrinogen and thrombin obtained from either pooling plasma cryoprecipitate from multiple human donors or from animal sources, e.g . Bovine. These products are prepared using laboratory drug regulated manufacturing processes including the need for pasteurization and filtration in order to eliminate harmful pathogens which might be transferred to the patient from such sources.
A further proven risk of these technologies is the risk of immune reaction originating from constituent parts associated to such pooled plasma sources. In addition the technologies are complicated by cold storage logistics, lengthy perioperative processing times and cost especially at higher volumes. These reasons have caused such products to be used with extreme caution or withdrawn altogether.
In order to avoid the risk associated with pooled plasma sources, autologous fibrin glues, sealants or gels have been proposed where fibrinogen and thrombin are obtained from a single donor.. Some of these fibrin products, however, had to rely on the combining of autologous fibrinogen with e.g . bovine thrombin, and thus still suffered from the risk or deficiencies associated with non-human products, e.g . an immune response against bovine plasma proteins.
For these reasons improved fibrin products and means for their preparation, where the fibrinogen and the thrombin components, were isolated from a single human donor blood or plasma sample for the use on that same donor have been proposed .
Several systems, tools or devices and methods as well have been brought forward and, at least for some of same, subsequently launched in order to satisfy this type of yet unmet medical need.
EP 0877 632 Bl, for example, refers to a method for preparing stepwise autologous fibrin glue for surgical use and comprising centrifugation of the blood sample to afford a supernatant consisting mainly of plasma including fibrinogen, concentrating fibrinogen in the plasma fraction by means of centrifugation and subsequent filtration and eventually freezing the concentrated plasma before use. Fibrin glue is obtained by mixing the thawed concentrated plasma fraction with a "suitable starter", indeed thrombin. Centrifugation is performed using interconnected plastic pouches constituting a closed system and the transfer of specific plasma fraction is indeed performed manually.
EP 1155 706 Al discloses an apparatus for producing "clinically ready fibrinogen of high concentration" and discloses a closed system, in fact an apparatus provided with means for receiving blood concentration from a patient, a plasma membrane separator to extract and separate the plasma from undesirable components, a second membrane separator to provide separation of fibrinogen.
A vacuum pump is connected to the fibrinogen collector; a freezer is used to provide adjustable temperatures to the various plasma fractions; communication means comprise at least one peristaltic pump to maintain plasma transport within the closed system. According to a specific embodiment the system further comprises a mixer to mix fibrinogen with an adequate concentration of autologous thrombin and calcium salt to form the fibrin glue.
EP 1420 833 refers to a system (apparatus) for producing an autologous platelet gel which makes use of an autologous anti-coagulated blood sample as starting material and comprises, among others, a first vessel comprising means for activating the blood components which then provides coagulated blood components and expresses eventually thrombin therefrom.
The said first vessel is fitted with an external filter having a pore size that allows thrombin to pass through it selectively, the filtered thrombin being then mixed with a separate portion of autologous blood components like red blood cells, white blood cells, platelet rich plasma (PRP), platelet poor plasma (PPP) which all result from the centrifugation of the initial autologous blood sample and which are stored in a second vessel, to form autologous platelet gel .
All these solutions and their equivalents present some drawbacks: the simplest systems, e.g. as defined in EP 0877 632 Bl, present the risks of disturbing the sterility inherent to hand manipulations, do not produce sufficient quantities to satisfy the needs of large surgeries, are impractical to operate during a surgical procedure, are too costly both in peri-operative labor input and materials and take too long thus not allowing the use of such systems during the course of the procedure.
Closed systems like those mentioned here above, or their equivalents, proved to be excessively complex to handle and to monitor, to be highly expensive in their use especially due to the necessity to clean and te decontaminate (if indeed possible at all) and to sterilize most of their parts for subsequent re-use and were therefore not adopted leaving ready to use recombinant or animal based products, stored frozen, as only practical, cost-economic technologies for surgeries requiring only small volumes of fibrin today thus still leaving an unmet medical need in those procedures, especially cardiac and orthopedic, requiring larger volumes > 10ml.
The invention obviates adequately all the obstacles still met in surgical process and responds to an obvious unmet medical need. The invention is defined in the claims appearing here below.
Summary of the Invention
A first object of the invention is a system useful for the treatment or the isolation of plasma or blood components including a specific support platform arranged to cooperate with a removable single-use device and which comprises means of mechanical actuation, means of mechanical or electro-magnetic or visual contact, means of thermal transfer, shaking means and means of control and command as well as a removable single-use device as defined here below. A second object of the invention is a removable single-use device for use in the above system and comprising : a) a first chamber of treatment 6 connected to the outside by two separate inlets 7b, 7a and an outlet filter 888, respectively, and further connected
to a storage chamber 9 leading eventually to the outside of device 2 via an outlet 8b, said first chamber 6 being also connected to b) a second chamber of treatment 10 connected to the outside by means of inlet 7a as well as by an outlet 8a, said second chamber being further connected to a mixing chamber 12 leading eventually to the outside of device 2 by means of outlet 8a, c) means 13a, 13b, 13c... for transferring the flows of liquids from a chamber to another one, respectively the flows of liquids or gas from the outside to the inside of device 2 or from the inside of device 2 to the outside, and d) means 14a, 14b, 14c... for controlling the flows of liquids from a chamber to another one, respectively flows of liquids from the outside to the inside of device 2 or from the inside of device 2 to the outside.
Another object of the invention is the use of the said system for the preparation of at least two autologous separate plasma fractions enriched in thrombin and fibrinogen respectively.
Still another object of the invention is the use of the said system for the extemporaneous preparation of autologous fibrin.
Still another object of the invention is the use of the said system for the preparation of a 3D fibrin cell preservation and cell growth and proliferation matrix.
Figures
Fig. 1 is a perspective view showing platform 1 fitted with the dedicated means which shall cooperate with corresponding means embedded in device 2.
Fig. 2 is a partial section view of both platform 1 and device 2.
Fig. 3 is a schematic representation of the inside of device 2.
Detailed description of the Invention
The system according to the invention comprises first the platform 1. This one includes, among others, mechanical means of activation 3a, 3b, 3c..., for example vertically connected axes each arranged in or connected to an embedded engine (not illustrated) and ordered to pull the corresponding
counterpart of a pump, such a peristaltic pump 3a, 3b, 3c..., e.g. located inside the removable device 2.
Each of the said engines pulling the above mentioned axes is individually controlled, for putting on or off the said pumps as well as for their rotation speed for example. This control is made by means of the centralized control and command unit 5a, such a microprocessor for example, according to a predefined and preset protocol : the said engines can be thus managed substantially automatically or, alternatively, according to own choices of the user. In this last case, the instructions of the user are transmitted throughout the aforementioned platform by means of for example a touch-sensitive screen 5a.
The platform 1 also includes mechanical, electromagnetic or even visual contact means 4a, 4b, 4c... These means can include for example pressure sensors, heat sensor or visible or infrared light detectors. These means of contact 4a, 4b, 4c... serve in particular to check and control the positioning (OPEN / CLOSED or ON / OFF) of valves 14a, 14b, 14c... located in the removable device 2 and, consequently, serve to manage or to regulate the various transfers of fluids throughout said device 2, for example from one chamber to another one or from the outside of device 2 towards an inside chamber like treatment chamber 6 or 10 or vice versa.
The platform 1 further includes means of thermal transfer 21 or 22, generally placed directly below the chambers subject to thermal transfer, in particular storage chamber 9 or mixing chamber 6. These means serve as well to warm than to cool the content of one or several of the chambers dedicated to that purpose and, also, to maintain the fluid content of these chambers at the desired temperature for a prolonged period if necessary. The platform 1 further comprises shaking means 22, generally placed directly below the chambers subject to shaking or agitation, in particular treatment chamber 6. Shaking means are such to perform by mere mechanical contact with the relevant location in the bottom of device 2, i.e. below chamber 6 for example or, alternatively, distal therefrom and by means of a rotating metal plate pulling a magnet placed in said chamber 6. The monitoring and the actuation of said shaking means is driven by means of the centralized control and command unit 5a.
These means of thermal transfer are also dependent on the control and command unit 5a mentioned here above and the temperatures or the selected temperature variations can be set in advance according to a pre-established and preset protocol or, alternatively, along to the progression of the fluid flows moving inside the removable device 2, i.e. whereby the necessary instructions are provided step by step by the user to said control and command unit.
According to the invention each of the chambers of device 2 is fitted with respective inlets 7a, 7b, 7c, 7d and outlets 8a, 8b, i.e. connecting devices generally used in the art to lock standard syringes to any pipe or pouch or bottle used in the medical or surgery domain.
Inside device 2 the chambers are interconnected by means of standard pipes, preferably flexible plastic tubing used conventionally for blood or plasma transfusion. This tubing 444, 444a, 444b, ... are either linear, circular or branched depending on their location and their functionality as well.
Inside both linear and branched pipes 444, 444a, 444b, ... there are located valves 14a, 14b, 14c, 14d, 14e, 14f, 14g, 14h, 14i, ... These valves represent the means necessary to monitor various transfers of fluids throughout device 2, from one chamber to another one and from the outside of device 2 to the inside, e.g . when the starting PPP sample is introduced into treatment chamber 6 or 10, or when thrombin is leaving storage chamber 9 to be transferred outside device 2 and when, the enriched fibrinogen plasma fraction is leaving simultaneously mixing chamber 12 to be transferred outside device 2. Valves 14a, 14b, 14c, ... are usually embedded mechanical or electro-magnetic valves as frequently met in medical devices used e.g. in blood transfusion and they are arranged to cooperate with the contact means mentioned here above. They can further comprise light sensors which easily detect if and when a pipe or a chamber is either full or empty. Pressure sensors can also act in a similar way.
According to a preferred embodiment of the invention actuating means 13 comprise peristaltic pumps 13a, 13b, 13c, 13d, 13e, ... arranged to cooperate with the corresponding engines such as those referred to above. The said cooperation is such that the mechanical actuating modalities of device 1 can enter the outer casing / housing of the disposable device at pre-designated design openings but are at all times in contact with the external aspects of the chambers and tubing of the internal closed circuit system so as to not come in direct contact with their sterile or biological content which would otherwise lead to contamination and risk of transfer of disease or infection.
The system of the invention also comprises means of thermal transfer 21, ensuring either the heating or the desired cooling of the plasma fractions temporarily left in a specific chamber. Heating and/or cooling can be performed by means of a suitable electric or other device, generally located at or close to the interface between platform 1 and device 2 but resident on platform 1 Heat transfer occurs usually by conduction, i.e. by mere physical contact between the relevant portions of platform 1 and device 2 involved.
The system of the invention enables separating and subsequently treating specific blood or plasma fraction and, eventually, recombining extemporaneously
duly selected blood or plasma components, in particular thrombin and fibrinogen generated from a single blood sample to afford fibrin, autologous fibrin more specifically. The sequence of the operations carried out when using the system of the invention is briefly described here below.
Whole blood is previously centrifuged and separated into three distinct fractions: red blood cells (RBC), platelet rich plasma (PRP) and platelet poor plasma (PPP). This centrifugation can be performed at point of care or several hours or days before surgery or tissue engineering or injection purposes, or during the surgery or procedure as required e.g ., by means of an external blood components separator, each of these fractions being then stored separately, in usual conditions.
The fraction consists of concentrated platelets, stem cells, tissue scaffold, etc. is kept temporarily in a separated vessel with the aim of its optional or delayed administration to the blood donor if applicable. In that purpose a standard syringe containing the desired amount of fraction to administer to the blood donor will be connected in due time to mixing chamber 12 by a tip 7c and a pipe portion 11 cooperating with the pump 13d .
A first portion of PPP is introduced into treatment chamber 6 via inlet 7a, by means of a standard syringe or other means; the plasma fluid is pulled in direction of said chamber 6 by means of peristaltic pump 13b while valve 14a is temporarily set to allow movement to tubing 444a and closed off to 444b whereby avoiding any fluid transfer through tubing 444b which is leading to the chamber 10. The valve 14i is simultaneously left closed towards said chamber 6 while avoiding any fluid transfer through pipe portion 444c leading to mixing chamber 9. Valve 14h is simultaneously set so that it opens towards 444 but is closed towards chamber 10.
A predefined portion of catalyst or reagent is then introduced into treatment chamber 6 via inlet 7b, e.g . by means of a syringe and the reagent mixture passed over negatively charged spheroids aided with agitation through shaking and thermal transfer from 22 on system 1 or by other means over a predefined period to afford thrombin rich plasma separation (rich being defined as e.g . >2x patient's own baseline). Valves 14a, 14g and 14ias well remain closed in order to avoid any other fluid transfer inside the device during this operation. The plasma fraction containing thrombin is then transferred through a filter 888 filtering out anything above molecular weight 6000, into tubing 444c to storage chamber 9, with valve 14i open for facilitation of movement, and stored therein at optimal temperature provided by thermal transfer from 21 on system 1 before its subsequent transfer to e.g . a double body syringe currently used in the art, via outlet 8b. A one way air filter valve 555a facilitates the priming of fluid into the
tubing between chamber 9 and exit 8b by eliminating air in that part of tubing prior to entering syringe 18a.
A second portion of PPP is introduced into treatment chamber 10 aided by 13b via same inlet 7a this time valve 14a opening towards 444b and shutting towards 444a and valve 14h open to 444 and inlet 7a while at same time closed to 444e where the PPP is subject to a concentration which can be carried out as described here after. As the PPP enters the circuit the air present therein pushed forward in the circuit and expressed into chamber 333 through valve 14b to effect priming of the circuitry removing any remnant air. Simultaneously chamber 16, which is an inflatable bag, is filled with a certain volume of PPP. The water initially present in the PPP fraction is progressively filtered off by means of hollow fibers with distinct cross-membrane pressure gradients e.g . a filter inside chamber 10 and subsequently moved with help of the circuit pressure created by pump 13b and placed into expandable chamber 333 via one-way valve 14b. Chamber 333 is initially a collapsible bag or vacuum filled container which receives air from initial priming of circuit with PPP and subsequently the water from the filtering process.
The open pipe connection undergoes a progressive aspiration which is applied from exit 14b e.g. by means of a negative pressure device induced through by example mechanical or other means on chamber 333. Simultaneously as water leaves the circuit through the filter the remaining volume of fluid / gas in the circuit is reduced. To accommodate for such a reduction in fluid in the circuitry, and to avoid a collapse of the tubing from the negative pressure this could cause, a variable size / volume chamber 16 is installed. During the filtration process as described valve 14h allows fluid to pass into and out of chamber, via 444e and 444 while being blocked off to tubing with inlet 7a.
One gets, eventually, over a predefined period, a concentrated PPP fraction having a high content of fibrinogen (e.g . >2.5x patient blood baseline values) which is then transferred directly to mixing chamber 12 and out through 8a while valve 14f is open. As concentrated fibrinogen fraction is expelled via outlet 8a into a standard syringe of the art valve 14c is open to tubing 444b but closed off to tubing 444d all the while being pulled through by pump 13e or 13b. In order for the circuit to purge it of its content air must be introduced through an air- filter 555 (to avoid negative vacuum pressure) and valve 14d must be set closed towards tubing 444b and open towards tubing 444d. Air then is able to enter the circuit to allow liquid content of the circuit to be expelled into mixing chamber 12 and into syringe through outlet 8a.
Provided red blood cells (see above) or a solution of any suitable chemical reagent or pharmaceutical component, such as an additive, or any additional biological tissue component such as fat, bone marrow concentrate or stromal vascular fraction among other, has to be added to the fibrinogen plasma fraction, peristaltic pump 13d is then started up rotating to take away the desired amount
of additive from its container, i.e. a syringe connected to standard connector inlet 7c and pulling said additive into mixing chamber 12. The simultaneous and computer steered action of pumps 13e or 13b, 13d and 13c will determine the ratio and thus mixtures of substances to be expelled through 8b and 8a into a double body syringe system with first syringe attached to outlet 8b and second syringe attached to outlet 8a. For purposes of further understanding these syringes are of different size and therefore when depressed at same rate will deliver a further exact ratio of mixing of substance from outlet 8b with that of outlet 8a. It is this ratio combination of fibrinogen and thrombin rich plasma fractions that will create the fibrin as the two mix e.g . on the wound / tissue surface.
The configuration of this mixing chamber 12 is generally such that the mixture of the two plasma fractions at stake is made by simple flow of components but may incorporate further means of mechanical mixing inside said chamber 12.
Autologous fibrin, eventually, is generated spontaneously from thrombin and fibrinogen when the content of each of the above cylinders is pushed off by the user.
Example (with reference to Fig 3) a) 180 ml of whole human blood containing required amount of anti-coagulant is centrifuged and separated into three distinct fractions: 1) ca. 70 ml of red blood cells (RBC); 2) ca. 5 ml of concentrated platelet rich plasma (PRP) and 3) ca. 105 ml of platelet poor plasma (PPP) after ca. 20 min. during the patient treatment procedure. As required by the treating physician a syringe containing all or a portion of the subsequent (diluted or undiluted) PRP fraction shall be placed in a syringe with standard "luer-lock" connection to mixing chamber 12 by inlet 7c and a pipe portion cooperating with the pump 13d. b) A first portion of 12 ml of PPP is introduced into treatment chamber 6 via inlet 7a, by means of for example a syringe connected to standard "luer-lock" inlet 7a; the plasma fluid is pulled in direction of said chamber 6 by means of peristaltic pump 13b while valve 14h is temporarily left open to tubing 444 but and chamber 16 but closed towards chamber 10 in order to avoid any fluid transfer through the tubing towards chamber 10. Simultaneously valve 14g is closed towards inlet 7b but open towards one way valve air filter outlet 555a. This allows the filling of tubing and chamber by displacing the air contained therein before use. Simultaneously valve 14i is closed during this process to avoid fluid moving prematurely into chamber 9.
A predefined portion of a reagent, for example 2.4ml ethyl alcohol, 1.15wt% CaCI2, is introduced into treatment chamber 6 via inlet 7b, e.g . by means of syringe and pulled through by pump 13a or injected by simple depression of the reagent syringe. The reagent and primed contents of chamber 6, which contains for example negatively, charged glass spheroids, and previously introduced PPP are mixed together by vibration agitation introduced externally from 22 of system 1 the device platform interface and then left to react for approximately 15 min. The plasma fraction rich in thrombin is then transferred through a filter 888 via valve 14i through tubing 444c into storage chamber 9 and stored therein at room temperature or chilled to 6 degrees Celsius if stored for longer durations (e.g . >45mins). c) A second portion of 105 ml PPP is introduced into treatment chamber 10 via inlet 7a and pipe portion 444, 444b and 444d via open valves 14h, 14a, 14c and 14d and wherein the PPP is then subject to a concentration which is carried out as follows: the water initially present in PPP is progressively filtered off by means of for example a hemodialysis plasma filter with filtering membranes where after the filtered water flows progressively out of said chamber 10 into the external reservoir 333.
The PPP concentration process happens via multiple passes of the PPP over the filtering membranes of chamber 10 in a closed circuit. For this a closed circuit has to be established which allows the volume of PPP to reduce as water is eliminated from it through one-way valve into chamber 333. Therefore the circuit comprising of 14h, tubing 444, pump 13b, valve 14a, tubing 444b, valve 14c, 14d, tubing 444d and chamber 10 must first be primed with PPP expelling all air in the circuit through valve 14b into chamber 333. To do this pump 13b activates and valves 14a, 14h, 14d, 14c turn in direction of circuit described with valve 14b open towards chamber 333. Thereby as PPP is pulled into inlet 7a from outside container / syringe the air in the system is expelled into chamber 333 which is made from an expandable material so as to inflate as air and subsequently water from the filtering process are expelled therein. Simultaneously valve 14h (being a 3 way valve) is also open to chamber 16. Chamber 16 is a variable chamber which as water exits the circuit and reduces in size to prevent buildup of negative pressure or vacuum from being created. .
One gets, eventually, over a period of approx. 5-10 minutes, a concentrated PPP fraction having a high content of fibrinogen, i.e. approx. 2.5 - 5 times higher than patient's own baseline. Once the required concentration is reached, as determined by sensors or timing, the contents can be expelled into mixing chamber 12 and subsequently into a syringe through outlet 8a. To do this the reverse of the priming, being purging, of the tubing system must occur. That requires the entry of air into the circuit without which the fluid could not be expelled. For this to happen, the same circuit as already described must reduce in volume consequently at the same ratio as the concentration i.e. the volume of
the expelled water. Chamber 16 reduces in size as filtration continues. This can be done simply by attaching a syringe whereby the plunger will automatically move up or down with the direction of the PPP priming or concentration processes. d) Provided platelet rich plasma, bone marrow derived stem cell concentrates, fat tissue, pharmaceuticals or any other substance are required to be mixed with the fibrinogen (for subsequent activation by the thrombin and/or to be embedded in the fibrin matrix) then these can be attached via a pre-filled syringe containing said substances to inlet 7c. The control system of the device will allow exact ratios of said substances to be mixed, in accordance with clinical requirements and protocols, with the fibrinogen and subsequently with the thrombin. In addition a simple rubber needle entry port, 7d, is also provided for addition of further pharmaceuticals if required .
Then, following user's instruction, peristaltic pumps 13c, 13d and 13e are started up simultaneously while 13b is pushing the fibrinogen plasma fraction referred to above out of the mixing chamber 12 into the first cylinder of a double body syringe provided with a single exit, whereas pump 13c is transferring by suction the stored thrombin out of the storing chamber 9 and transfers the latter into the second cylinder of the double body syringe provided with a single exit 8b. All of these actions can also be done by pulling on the syringe handles of 18a or 15 in order to create negative pressure onto the circuitry and thereby pull the contents into syringe as required, manually, by the operator. In such a case a mechanism to ensure free movement of valves and pumps is envisaged .
Autologous fibrin, eventually, is generated spontaneously from thrombin and fibrinogen when the content of each of the above cylinders is pushed off by the user.
Claims
A system for the treatment and/or the isolation of plasma or blood components including a support platform (1) arranged to cooperate with a removable single-use device (2) and comprising means of mechanical actuating (3a, 3b, 3c ...), means of mechanical or electro-magnetic or visual contact (4a, 4b, 4c ...), means of thermal transfer (21), shaking means (22) and means of control and command (5a), said removable single-use device (2) comprising : a) first chamber of treatment (6) connected to the outside by two separate inlets (7b, 7a) and an outlet filter 888, respectively, and further connected to a storage chamber (9) leading eventually to the outside of device (2) via an outlet (8b), b) a second chamber of treatment (10) connected to the outside by means of inlet (7a) as well as by an outlet (8a), said second chamber being further connected to a mixing chamber (12) leading eventually to the outside of device (2) by means of outlet (8a), c) means (13a, 13b, 13c ...) for transferring the flows of liquids from a chamber to another one, respectively the flows of liquids or gas from the outside to the inside of device (2) or from the inside of device (2) to the outside, and d) means (14a, 14b, 14c ...) for controlling the flows of liquids from a chamber to another one, respectively the flows of liquids from the outside to the inside of device (2) or from the inside of device (2) to the outside.
The system according to claim 1 wherein means (13a, 13b, 13c ...) consist of embedded dedicated peristaltic pumps arranged to cooperate with the mechanical actuating means (3a, 3b, 3c ...) of support platform (1).
The system according to any of the preceding claims wherein means ( 14a, 14b, 14c.) comprise embedded dedicated electro-magnetic valves or light sensors arranged to cooperate with the means of contact (4a, 4b, 4c ...) of support platform (1).
The system according to any of the preceding claims wherein storage chamber (9) is a controlled temperature chamber which is arranged to
cooperate with the means of thermal transfer (21,) of support platform (1).
5. The system according to any of the preceding claims wherein mixing chamber (12) is connected to an external container (15).
6. The system according to any of the preceding claims wherein means of control and command (5a) comprise actuating means and sensors dedicated to control the flows of liquids or gas, actuating means and sensors dedicated to control the introduction of exogenous components in the selected chambers as well as actuating means and sensors dedicated to control the outlet of the treated and/or isolated blood or plasma fractions or components.
7. The system according to any of the preceding claims wherein means of control and command (5a) are driven by a computer controlled protocol designed for monitoring the input of blood or plasma components as well as the introduction of exogenous components into selected chambers of device (2) and the outlet of the treated or isolated blood or plasma fractions or components as well.
8. The system according to any of the preceding claims which further comprises an external blood component separator (999) connected to inlet (7a).
9. The system according to any of the preceding claims which comprises a variable size/volume chamber (16) connected to a closed circuit comprising (444, 444b, 444d), treatment chamber (10), chamber (16) and (444e).
10. The system according to any of the preceding claims which comprises an expandable chamber (333) connected to treatment chamber (10) via a one-way valve.
11. The system according to any of the preceding claims which comprises an air-filter (555) located between treatment chamber (10) and mixing chamber (12).
12. The use of the system of any of claims 1 to 11 for the preparation of at least two separate plasma fractions both enriched in thrombin and fibrinogen respectively, which comprises : a) introducing a predefined first amount of a poor platelet plasma fraction into treatment chamber (6) fitted with suitable reagent and activators as well as introducing a predefined second amount of a poor platelet
plasma fraction into tubing circuit 444, 444b, 444d, treatment chamber (10), 444e and chamber 16; b) adding an exogenous activator comprising ethyl alcohol and calcium chloride or similar to the poor platelet plasma fraction of chamber (6) and subjecting the resulting mixture to shaking at 37° C with shaking means (22) in cooperation with thermal transfer means (21) of platform (1), subsequent filtering through 888 and transfer of the activated thrombin plasma fraction into storage chamber (9); c) subjecting the poor platelet plasma fraction of chamber (10) to a concentration step by means of elimination of water from said chamber (10); d) transferring the resulting concentrated plasma fraction enriched in fibrinogen to mixing chamber (12) and optionally adding thereto either other autologous blood components or exogenous ingredients; e) transferring the resulting enriched fibrinogen fraction outside device (2), and f) transferring simultaneously the enriched thrombin fraction temporarily stored in chamber (9) outside device 2.
13. The use according to claim 12 which comprises introducing first a blood sample into the external blood component separator (999), separating the blood components of said sample and isolating therefrom a platelet poor plasma fraction which is then introduced into chambers (6) and (10), respectively.
14. The use according to any of claims 12 and 13 which comprises transferring temporarily both the enriched fibrinogen fraction and the enriched thrombin fraction into two separate containers (18a, 15).
15. The use according to any of claims 12 to 14 for the preparation of autologous fibrin which comprises contacting eventually both the enriched fibrinogen plasma fraction and the thrombin plasma fraction temporarily stored in containers (18a) and (15) at the outside of device (2).
16. A device for the treatment and/or the isolation of plasma or blood components consisting of a removable single-use device (2) comprising : a) a first chamber of treatment (6) connected to the outside by two separate inlets (7b, 7a) and an outlet filter (888), respectively, and further connected to a storage chamber (9) leading eventually to the
outside of device (2) via an outlet (8b), said first chamber being also connected to b) a second chamber of treatment (10) connected to the outside by means of inlet (7a) as well by outlet (8a), respectively, said second chamber being further connected to a mixing chamber (12) leading eventually to the outside of device (2) by means of outlet (8a), c) means (13a, 13b, 13c ...) for transferring the flows of liquids from a chamber to another one, respectively the flows of liquids or gas from the outside to the inside of the device or from the inside of device (2) to the outside, and d) means (14a, 14b, 14c ...) for controlling the flows of liquids from a chamber to another one, respectively the flows of liquids from the outside to the inside of the device or from the inside of device (2) to the outside, said device (2) being arranged to cooperate with a support platform (1) comprising means of mechanical actuating (3a, 3b, 3c ...), means of mechanical or electro-magnetic contact or visual contact (4a, 4b, 4c ...), means of thermal transfer (21,) shaking means (22) and means of control and command (5a).
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2013/061397 WO2014194930A1 (en) | 2013-06-03 | 2013-06-03 | Extemporaneous preparation of autologous fibrin |
EP14730795.3A EP3003418B1 (en) | 2013-06-03 | 2014-06-02 | Extemporaneous preparation of autologous fibrin |
JP2016516196A JP2016524500A (en) | 2013-06-03 | 2014-06-02 | Instant preparation of self-fibrin |
CN201480031385.6A CN105307697A (en) | 2013-06-03 | 2014-06-02 | Extemporaneous preparation of autologous fibrin |
US14/895,817 US10300188B2 (en) | 2013-06-03 | 2014-06-02 | Extemporaneous preparation of autologous fibrin |
PCT/EP2014/061327 WO2014195252A2 (en) | 2013-06-03 | 2014-06-02 | Extemporaneous preparation of autologous fibrin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2013/061397 WO2014194930A1 (en) | 2013-06-03 | 2013-06-03 | Extemporaneous preparation of autologous fibrin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EPPCT/EP2013/067040 Continuation-In-Part | 2013-06-03 | 2013-08-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/895,817 Continuation-In-Part US10300188B2 (en) | 2013-06-03 | 2014-06-02 | Extemporaneous preparation of autologous fibrin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014194930A1 true WO2014194930A1 (en) | 2014-12-11 |
Family
ID=48607228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/061397 WO2014194930A1 (en) | 2013-06-03 | 2013-06-03 | Extemporaneous preparation of autologous fibrin |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014194930A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111102783A (en) * | 2019-11-29 | 2020-05-05 | 西华大学 | Energy-saving system of refrigeration house and control method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000016872A1 (en) * | 1998-09-21 | 2000-03-30 | Purdum Howard E | Methods and apparatus for processing temperature sensitive materials |
EP1155706A1 (en) | 2000-05-19 | 2001-11-21 | Xun Yang Huang | Apparatus for production of fibrin glue and its medical application |
EP0877632B1 (en) | 1996-09-18 | 2003-03-19 | Flavio Tarantino | Process of preparation of an autologous fibrin glue |
EP1420833A2 (en) | 2001-04-09 | 2004-05-26 | Medtronic Inc. | System for the production of autologous platelet |
EP1625861A1 (en) * | 2003-05-21 | 2006-02-15 | JMS Co. Ltd. | Container for serum production and method of regenerative medicine using the same |
EP2520316A2 (en) * | 2011-05-02 | 2012-11-07 | Biomet Biologics, LLC | Thrombin isolated from blood and blood fractions |
-
2013
- 2013-06-03 WO PCT/EP2013/061397 patent/WO2014194930A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0877632B1 (en) | 1996-09-18 | 2003-03-19 | Flavio Tarantino | Process of preparation of an autologous fibrin glue |
WO2000016872A1 (en) * | 1998-09-21 | 2000-03-30 | Purdum Howard E | Methods and apparatus for processing temperature sensitive materials |
EP1155706A1 (en) | 2000-05-19 | 2001-11-21 | Xun Yang Huang | Apparatus for production of fibrin glue and its medical application |
EP1420833A2 (en) | 2001-04-09 | 2004-05-26 | Medtronic Inc. | System for the production of autologous platelet |
EP1625861A1 (en) * | 2003-05-21 | 2006-02-15 | JMS Co. Ltd. | Container for serum production and method of regenerative medicine using the same |
EP2520316A2 (en) * | 2011-05-02 | 2012-11-07 | Biomet Biologics, LLC | Thrombin isolated from blood and blood fractions |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111102783A (en) * | 2019-11-29 | 2020-05-05 | 西华大学 | Energy-saving system of refrigeration house and control method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4173205B2 (en) | Preparation of plasma and fibrin gel for autologous transplantation | |
US10300188B2 (en) | Extemporaneous preparation of autologous fibrin | |
KR102109317B1 (en) | Method and device for fast dissolution of solid protein composition | |
US8871526B1 (en) | Apparatus for obtaining growth factors | |
JP2017051665A (en) | Method for preparation of at least one compound from blood, and extraction device for use in execution of said method | |
US10045526B2 (en) | Method and apparatus for cryopreservation of blood cells in a sterile environment | |
WO2011049709A1 (en) | Methods and systems for providing red blood cell products with reduced plasma | |
RU2017103172A (en) | DEVICES AND METHODS FOR PRODUCING INJECTION SCLEROPENES FOR VESSELS BY USING A MATRIX CARRIER AND THEIR APPLICATION | |
JP2016504165A (en) | Devices and methods for platelet lysis or activation | |
KR20140051281A (en) | Coagulation controlling agents and devices comprising the same | |
EP2602310B1 (en) | Autoserum-containing bone marrow cell culture system, autoserum-containing bone marrow cell culture method, and method for producing medicinal composition comprising autoserum-containing cultured bone marrow cells as active ingredient | |
WO2014194930A1 (en) | Extemporaneous preparation of autologous fibrin | |
EP3003418B1 (en) | Extemporaneous preparation of autologous fibrin | |
JP2013531541A (en) | Apparatus and method for processing biomaterials in a closed system | |
US9861736B2 (en) | Methods for extracting platelet-rich plasma for therapeutic injection | |
US20110282325A1 (en) | Dehydrated plasma kit | |
CN107638602A (en) | A kind of filter and preparation method and application placed in the blood vessel | |
EP3100710A1 (en) | Syringe for cell isolation | |
EP3669904A1 (en) | Methods and systems for platelet cryopreservation | |
CA3213799A1 (en) | System and solution for improved whole blood storage | |
EP3171778B1 (en) | Kit for cord blood collection | |
EP3558411A1 (en) | Device and methods for platelet lysis or activation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13728145 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 15/03/2016) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13728145 Country of ref document: EP Kind code of ref document: A1 |